fsa tirzepatide Compounded (GLP-1) 22% body weight HSA Eligibility for GLP-1 Weight

GHK-Cu represents a scientifically-supported approach to tissue regeneration with applications spanning skin health, hair restoration, and wound healing

The rationale for blending these two peptides stems from their non-overlapping receptor targets and complementary metabolic effects: Amylin Pathway (Cagrilintide): Targets amylin receptors in the brainstem Creates meal-specific satiety signals Slows gastric emptying through distinct mechanisms Reduces meal size and eating frequency Triple Agonist Pathway (Retatrutide): Activates GIP, GLP-1, and glucagon receptors Enhances insulin secretion and glucose metabolism Increases energy expenditure through glucagon effects Provides broader metabolic regulation When combined, these pathways could theoretically provide additive or synergistic effects on weight management and metabolic function

Avoid its use during breastfeeding due to the possibility of passing its effects to the infant

Childs Nervous System 26(2):221226

They appear to reduce intestinal inflammation and support healthy intestinal barrier function